Navigation Links
Cephalon Exercises its Option to Acquire BioAssets Development Corporation
Date:10/21/2010

ciatica."  

The merger agreement is subject to customary closing conditions.  Upon the closing of the merger, Cephalon would purchase all of the outstanding capital stock of BDC for $12.5 million, subject to net working capital and debt adjustments set forth in the merger agreement.  BDC already received $30 million for the Cephalon option to acquire BDC, and shareholders could receive additional payments related to regulatory and sales milestones.  BDC was advised on this transaction by Extera Partners.  

About Cephalon, Inc.Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas.  Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide.  The company sells numerous branded and generic products around the world.  In total, Cephalon sells more than 150 products in nearly 100 countries.  More information on Cephalon and its products is available at www.cephalon.com.

About BioAssets Development CorporationBioAssets Development Corporation is a private company pioneering novel spine indications for emerging and marketed biologic drugs. The Company's lead initiative focuses on the development of a TNF inhibitor therapy to treat the underlying cause of pain in sciatica.  For more information, visit www.biodevco.com.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements.  Forward-looking statements provide Cephalon's curre
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ("Galmed"), ... and commercialization of a once-daily, oral therapy for ... today announced financial results for the 12 months ... 2014 Highlights: , Hosted a key opinion ... Rohit Loomba, MD, MHSc., who discussed the topic ...
(Date:3/31/2015)... , March 31, 2015  CVS Health (NYSE: ... into new clinical affiliations with Rush University Medical ... and Tucson Medical Center in Tucson, ... Arizona Connected Care. These affiliations will help enhance ... patients. Through these clinical affiliations, CVS Health will ...
(Date:3/31/2015)... , March 31, 2015  Oxis International, Inc. (OXIS) ... development and commercialization, announced today Oxis CEO Tony ... of Oxis common shares on the Euronext exchange. Oxis ... the symbol OXIS.   Oxis Chairman and ... to move forward with its strategies launched in 2014 ...
Breaking Medicine Technology:Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 3Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 4Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 5Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 6Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 7Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 8CVS Health Announces New Clinical Affiliations with Leading Medical Centers in Arizona and Illinois 2CVS Health Announces New Clinical Affiliations with Leading Medical Centers in Arizona and Illinois 3Oxis International Inc. Announces Request for Euronext Trading Suspension 2
... Mich., and GERMANTOWN, Md., Nov. 21, 2011 Adeona ... a developer of innovative disease-modifying medicines for serious ... Corporation, a synthetic biology company that utilizes its ... announced today the formation of a global exclusive ...
... 18, 2011 Breast cancer patients, their families and ... Administration (FDA) decision to remove the anti-cancer drug Avastin ... stage breast cancer. Terry Kalley, founder of ... condemned the decision, saying, "While this vote is highly ...
Cached Medicine Technology:Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension 2Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension 3Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension 4Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension 5Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension 6Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension 7
(Date:3/31/2015)... 2015 OnChip Devices , a world ... silicon ESD diode chip targeted towards low voltage LED applications. ... Zeners are ideal for protecting circuits by suppressing voltage higher ... handle pulses of up to 350W and 20A, providing protection ... 61000-4-2 standard. These diodes do not exhibit any device ...
(Date:3/31/2015)... Clinovo, a leading provider of cloud-based ... the premiere voice of Northern California’s Life Science ... , BayBio brings together the collective strength ... productive life science cluster, helping companies grow, connect ... pressing challenges. , “We are thrilled to ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 At Summit Breast ... all patients in a calm and caring manner. , Summit ... diagnosis and surgical treatment of breast cancer. They treat ... but from all over the world. Their doctors continue ... publications. , The seeds for Summit Breast Care were planted ...
(Date:3/31/2015)... 2015 Beckman Coulter is sponsoring a ... “Subvisible Particulate Matter in Therapeutic Protein Injections”,” an educational session ... in counting particles in liquids, with a focus on the ... free to attend and will be broadcast live April 8, ... new test for protein-based materials, known as USP 787 ...
(Date:3/31/2015)... 31, 2015 BESLER Consulting today ... “The Value of an Independent Cost Report Review.” ... a critical role in the determination of Medicare ... appropriate understanding and review, this report can assist ... planning. , This white paper discusses:, ...
Breaking Medicine News(10 mins):Health News:OnChip Introduces Low Voltage Diodes for High-Brightness LED Protection 2Health News:Clinovo Joins BayBio Membership Program, The Leading Life Science Association in Northern California 2Health News:Summit Breast Care is Celebrating Four Years as "NJ Top Docs" 2Health News:Beckman Coulter Webinar Series Presents Insight into New Demands in Counting Particles in Liquids 2Health News:Beckman Coulter Webinar Series Presents Insight into New Demands in Counting Particles in Liquids 3
... Those with high levels of Epstein-Barr antibodies double their ... 7 (HealthDay News) -- Smoking appears to enhance the ... nearly doubling the chances of getting the disabling neurologic ... risk factor is having high levels of antibodies to ...
... Studying patients with kidney cancer, a team of researchers at ... a pair of proteins excreted in the urine that could ... The research, published online in the May issue of ... proteins secreted in urine that appear to accurately reveal the ...
... Henry Ford Hospital have found that infection with the ... cancer. Using administrative data from more than 67,000 ... the period 1997-2008, 0.6% (17/3057) patients with hepatitis C ... without the disease developed kidney cancer. After ...
... insight into patterns, coloring for species generally , WEDNESDAY, ... learned the long-sought-after secret of how animals make spots, ... a species of fruit fly ( Drosophila guttifera ) ... spots. Researchers found that morphogen -- a protein present ...
... drug might reverse genetic process that leads to disease, ... Researchers may have found an easy way to detect ... as well as a way to reverse the start ... drug. , "It,s incredibly, incredibly exciting," said Dr. ...
... levels of copper and iron to Alzheimer,s disease, heart disease, ... Chemical Research in Toxicology suggests specific steps that older ... of these metals in their bodies. "This story of copper ... of public health significance, is virtually unknown to the general ...
Cached Medicine News:Health News:Smoking May Boost MS Risk in Some 2Health News:Smoking May Boost MS Risk in Some 3Health News:Urine test for kidney cancer a step closer to development 2Health News:Urine test for kidney cancer a step closer to development 3Health News:Henry Ford Hospital atudy: Hepatitis C infection doubles risk for kidney cancer 2Health News:Science Reveals Secrets of Animals' Spots, Stripes 2Health News:Simple Test May Spot Early Lung Cancer 2Health News:Simple Test May Spot Early Lung Cancer 3
Inquire...
... the elegant and sophisticated woman, ... includes ophthalmic and sunwear styles. ... variety of shapes and colors, ... shapes and complexions. Many styles ...
... updated styling through the use of innovative ... collection is for the value driven consumer ... Eyewear Collection , The futuristic quality ... of the "strongest and lightest metal on ...
Inquire...
Medicine Products: